Stock ECX EPIGENOMICS AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Epigenomics AG Xetra

Equities

ECX

DE000A3H2184

Delayed Xetra
Other stock markets
 11:36:16 2022-12-23 am EST 		5-day change 1st Jan Change
1.512 EUR -0.26% Intraday chart for Epigenomics AG +0.27% -41.03%
Mar. 14 Epigenomics AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company appears to be poorly valued given its net asset value.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
EPIGENOMICS AG Stock Epigenomics AG
-41.03% 1.52M -
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-17.60% 11.52B
A-
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+39.11% 3.27B
D+
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-20.67% 2.02B -
B-
VERACYTE, INC. Stock Veracyte, Inc.
-29.30% 1.44B
C+
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+11.45% 1.01B
B-
SEEGENE, INC. Stock Seegene, Inc.
-6.33% 719M
C+
CAREDX, INC Stock CareDx, Inc
-30.75% 418M
C-
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
-51.02% 339M
C-
CURIOX BIOSYSTEMS CO., LTD Stock Curiox Biosystems Co., Ltd
-2.58% 284M - -
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
-
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. ECX Stock
  4. ECX Stock
  5. Ratings Epigenomics AG